Kornek G, Depisch D, Temsch E M, Scheithauer W
Department of Internal Medicine I, Wilhelminenspital, Vienna, Austria.
J Cancer Res Clin Oncol. 1991;117(5):493-6. doi: 10.1007/BF01612773.
To establish further the clinical significance of the CA-195 tandem immunoradiometric assay in gastro-intestinal malignancies, the sera of a total of 222 subjects have been analysed and compared with assays of the "classical gastrointestinal tumour markers", CA19-9 and carcinoembryonic antigen (CEA). CA-195 elevations above normal (greater than 10 U/ml) were noted in 51/72 (70.8%) colorectal, 15/15 (100%) pancreatic, and in 6/12 (50%) gastric cancer patients. Whereas CA19-9 was increased (greater than 37 U/ml) in 65%, 93%, and 42% of cases, only 54% colorectal, 45% pancreatic, and 42% gastric cancer patients had pathologically elevated serum CEA levels (greater than 5 ng/ml). No abnormal increase of both CA-195 and CA19-9 was found in healthy volunteers, whereas 3/20 (smoking) individuals had CEA levels slightly above normal. With a 29% false-positive rate noted among 103 patients with benign gastrointestinal disorders, the specificity of CA-195 was superior to that of CA19-9 (58%) and comparable with that of CEA (31%). A significant correlation between CA-195 levels and the clinical/pathological stage of disease was noted in colorectal (P less than 0.01) and pancreatic cancer patients (P less than 0.007). Preliminary results of serial measurements of CA-195 in colorectal cancer suggest that this new marker protein, which has no cross-reactivity with CEA, may be useful as a non-invasive test for postoperative surveillance of patients to detect disease recurrence, and serve to complement (though certainly not replace) standard clinical measurements of response to chemotherapy.
为进一步确定CA - 195串联免疫放射分析在胃肠道恶性肿瘤中的临床意义，对总共222名受试者的血清进行了分析，并与“经典胃肠道肿瘤标志物”CA19 - 9和癌胚抗原（CEA）的检测结果进行了比较。在72例结直肠癌患者中有51例（70.8%）、15例胰腺癌患者全部（100%）以及12例胃癌患者中有6例（50%）的CA - 195水平高于正常（大于10 U/ml）。而CA19 - 9在65%、93%和42%的病例中升高（大于37 U/ml），只有54%的结直肠癌、45%的胰腺癌和42%的胃癌患者血清CEA水平病理性升高（大于5 ng/ml）。健康志愿者中未发现CA - 195和CA19 - 9两者均异常升高，而20名（吸烟）个体中有3名的CEA水平略高于正常。在103例良性胃肠道疾病患者中，CA - 195的假阳性率为29%，其特异性优于CA19 - 9（58%），与CEA（31%）相当。在结直肠癌（P < 0.01）和胰腺癌患者（P < 0.007）中，CA - 195水平与疾病的临床/病理分期之间存在显著相关性。对结直肠癌患者进行CA - 195系列测量的初步结果表明，这种与CEA无交叉反应的新标志物蛋白，可作为术后监测患者疾病复发的非侵入性检测手段，并有助于补充（当然不能替代）化疗反应的标准临床测量。
